Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
Korean Circulation Journal
; : 557-560, 2013.
Article
de En
| WPRIM
| ID: wpr-24540
Bibliothèque responsable:
WPRO
ABSTRACT
Glycoprotein IIb/IIIa antagonists are well established for their effectiveness in improving clinical outcomes in acute coronary syndrome patients undergoing percutaneous coronary intervention. Acute profound thrombocytopenia is a rare complication of abciximab. We present a case which was managed successfully for the rare complication of acute profound thrombocytopenia after using abciximab and an intra-aortic balloon pump for the treatment of a no-reflow phenomenon and consecutive cardiogenic shock during primary percutaneous coronary intervention.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Choc cardiogénique
/
Thrombopénie
/
Fragments Fab d'immunoglobuline
/
Syndrome coronarien aigu
/
Phénomène de non reperfusion
/
Intervention coronarienne percutanée
/
Anticorps monoclonaux
/
Infarctus du myocarde
Limites du sujet:
Humans
langue:
En
Texte intégral:
Korean Circulation Journal
Année:
2013
Type:
Article